Winterlight Labs, a developer of digital biomarkers for the analysis of speech and language in neurological conditions, and Genentech, a member of the Roche Group, recently announced new data showing the sensitivity of speech-based digital measures in detecting disease-related longitudinal change in Alzheimer’s disease.
Using data from Genentech’s Tauriel trial of semorinemab in early-stage Alzheimer’s disease (NCT03289143), these analyses provide new evidence that automated measures for assessing patient speech can characterize longitudinal decline with comparable sensitivity to clinician-administered neuropsychological assessments. Digital measures can allow for better characterization of speech and language patterns, improved insight into the effects of novel treatments, and could support a shift to more hybrid or remote trial designs.